Literature DB >> 15219005

Lung function 5 yrs after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide.

M B Lund1, L Brinch, J Kongerud, J Boe.   

Abstract

Long-term data on lung function after bone marrow transplantation (BMT) are inconclusive. Previously, a persistent reduction in gas transfer 1 yr after allogeneic BMT with busulphan and cyclophosphamide conditioning was reported by the current authors. In the present study this reduction was examined to see if it was permanent, transient or progressive. Prospectively, 43 consecutive adult patients with malignant blood disorders undertook lung function measurements prior to BMT, at 3 month intervals during the 1st yr after BMT and finally after 5 yrs. Mean baseline lung function values were >90% predicted. Within the 1st yr after BMT a transient decline in lung volumes and a persistent reduction in gas transfer were observed. After 5 yrs, baseline values were restored for all variables, except in four patients who developed obliterative bronchiolitis. Acute leukaemia and smoking were independently associated with gas transfer reductions at baseline and during the 1st yr after BMT. Allogeneic bone marrow transplantation with busulphan and cyclophosphamide conditioning was associated with a reduction in gas transfer 1 yr after bone marrow transplantation but baseline values were usually restored after 5 yrs. Since recovery may be gradual and slow, an observation period >1 yr is required before drawing conclusions concerning the development of a permanent reduction in lung function after allogeneic bone marrow transplantation conditioned with busulphan and cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15219005     DOI: 10.1183/09031936.04.00084804

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  [Complications after allogeneic bone marrow and stem cell transplantation].

Authors:  E Wollmer; A Neubauer
Journal:  Internist (Berl)       Date:  2014-05       Impact factor: 0.743

2.  Effect of irradiation/bone marrow transplantation on alveolar epithelial type II cells is aggravated in surfactant protein D deficient mice.

Authors:  Christian Mühlfeld; Jens Madsen; Rose-Marie Mackay; Jan Philipp Schneider; Julia Schipke; Dennis Lutz; Bastian Birkelbach; Lars Knudsen; Marina Botto; Matthias Ochs; Howard Clark
Journal:  Histochem Cell Biol       Date:  2016-08-26       Impact factor: 4.304

Review 3.  Busulfan-Induced Lung Injury in Pediatric Oncology Patients-Review of the Literature with an Illustrative Case.

Authors:  Nusa Matijasic; Aleksandra Bonevski; Visnja Tokic Pivac; Ivan Pavic
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2019-09-17       Impact factor: 1.349

4.  Hepatic Sinusoidal-obstruction Syndrome and Busulfan-induced Lung Injury in a Post-autologous Stem Cell Transplant Recipient.

Authors:  Richa Jain; Kirti Gupta; Anmol Bhatia; Arun Bansal; Deepak Bansal
Journal:  Indian Pediatr       Date:  2017-09-15       Impact factor: 1.411

5.  Stable long-term pulmonary function after fludarabine, antithymocyte globulin and i.v. BU for reduced-intensity conditioning allogeneic SCT.

Authors:  S Dirou; F Malard; A Chambellan; P Chevallier; P Germaud; T Guillaume; J Delaunay; P Moreau; B Delasalle; P Lemarchand; M Mohty
Journal:  Bone Marrow Transplant       Date:  2014-02-17       Impact factor: 5.483

6.  The effect of smoking on allogeneic transplant outcomes.

Authors:  David I Marks; Karen Ballen; Brent R Logan; Zhiwei Wang; Kathleen A Sobocinski; Andrea Bacigalupo; Linda J Burns; Vikas Gupta; Vincent Ho; Philip L McCarthy; Olle Ringdén; Harry C Schouten; Matthew Seftel; J Douglas Rizzo
Journal:  Biol Blood Marrow Transplant       Date:  2009-08-03       Impact factor: 5.742

7.  The acute impact of a hematopoietic allograft on lung function and inflammation: a prospective observational study.

Authors:  Alexandra Enocson; Richard Hubbard; Tricia McKeever; Nigel Russell; Jennifer Byrne; Emma Das-Gupta; Lynne Watson; Andrew W Fogarty
Journal:  BMC Pulm Med       Date:  2013-01-11       Impact factor: 3.317

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.